In summary, we identified and validated a novel five-miRNA signature with independent prognostic significance for GBM patients with MGMT promoter methylation that can be a useful tool for identifying patients who would most benefit from alkylating chemotherapy treatment. This evidence concerns the gene MGMT and glioblastoma.